{
    "clinical_study": {
        "@rank": "14812", 
        "arm_group": [
            {
                "arm_group_label": "Arm A: Cetuximab", 
                "arm_group_type": "Active Comparator", 
                "description": "Cetuximab 500 mg/m2 every 2 weeks"
            }, 
            {
                "arm_group_label": "Arm B: Cetuximab and Capecitabine", 
                "arm_group_type": "Active Comparator", 
                "description": "Cetuximab 500 mg/m2 every 2 weeks plus Capecitabine 1000 mg/m2 (*) bid d1-14 every 3 weeks\n* 750 mg/m2 if creatinine-clearance 30-50 ml/min"
            }
        ], 
        "brief_summary": {
            "textblock": "OBJECTIVE: The objective of the trial is to judge on the benefit obtained by an upfront\n      cetuximab treatment delivered as monotherapy or as part of a combination treatment with\n      capecitabine in vulnerable elderly patients selected for V-Ki-ras2 Kirsten rat sarcoma viral\n      oncogene homolog (KRAS) wild-type and B-type Raf kinase (BRAF) wild-type metastatic\n      colorectal cancer (mCRC)."
        }, 
        "brief_title": "Cetuximab for Elderly Patients With mCRC", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Primary endpoint: If in a treatment arm the number of patients alive and without progression\n      at 12 weeks is 17 or more, this arm will be considered promising, otherwise not promising.\n      Additionally, a two-sided 95% confidence interval for the difference in Progression free\n      survival (PFS) rates between the two arms will be calculated.\n\n      Secondary endpoints and patient characteristics:\n\n        -  Laboratory values may be expressed as the absolute values (continuous variables) or/and\n           as grading (ordinal categorical variables).\n\n        -  Generally for each categorical variable the results will be summarized by frequencies\n           and percentages. For response rates 95% Clopper-Pearson confidence intervals will be\n           calculated.\n\n        -  For each adverse event, the results will be summarized by frequencies and percentages\n           of different grades among all cycles as well as by frequencies and percentages of the\n           within-patient worst grades\n\n        -  For each continuous variable the results will be summarized by descriptive statistics.\n\n        -  Time-to-event variables will be presented by Kaplan-Meier curves and summarized by\n           medians and 95% confidence intervals.\n\n        -  All analysis will be done by treatment arm."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient has given written informed consent before any trial specific treatment\n\n          -  Histological proven diagnosis of colorectal cancer, metastatic or inoperable\n             advanced, not amenable to curative therapy\n\n          -  Measurable disease, defined as at least one lesion (outside of irradiated areas) that\n             can be measured in at least one dimension as \u2265 10 mm (\u2265 15 mm in case of lymph nodes)\n             according to RECIST v1.1\n\n          -  Tumour with wild-type KRAS and wild-type BRAF gene\n\n          -  No previous systemic chemotherapy for metastatic disease (previous adjuvant\n             chemotherapy is allowed if completed >6 months before randomization, previous rectal\n             radio-chemo therapy if completed >1 month before randomization)\n\n          -  WHO performance status 0 or 1\n\n          -  Age >75 years; or: age \u2265 70 years with at least one of the following factors:\n\n          -  Any functional dependence as measured by Instrumental Activities of Daily Life\n             (IADL). Significant comorbidity according to the Cumulative Illness Rating Scale for\n             geriatric patients (CIRS-G; any severe comorbidity > grade 3 or a total score > 5\n             qualifies)\n\n          -  Neutrophils \u2265 1.5 x 109/L, platelets \u2265 100 x 109/L\n\n          -  Bilirubin \u2264 2.0 x Upper Limit of Normal (ULN) (unless known Gilbert-Meulengracht\n             syndrome), aspartate aminotransferase (AST)<2.5xULN\n\n          -  Calculated creatinine clearance \u2265 30 ml/min. (according to the formula of\n             Cockcroft-Gault)\n\n          -  Patient is able to swallow oral medication\n\n          -  Baseline Quality of Life forms have been completed\n\n        Exclusion Criteria:\n\n          -  Documented or suspected cerebral and/or leptomeningeal metastases (no cerebral\n             baseline imaging required in asymptomatic patients)\n\n          -  Risk of rapid deterioration due to tumor symptoms or tumor complications\n\n          -  Synchronous or prior malignancy other than adequately treated non-melanomatous skin\n             cancer or in situ carcinoma of the cervix, other malignancies unless disease free > 2\n             years\n\n          -  Prior anti-EGFR (Epidermal Growth Factor Receptor) antibody therapy\n\n          -  Severe or uncontrolled cardiovascular disease (e.g. acute coronary syndromes, cardiac\n             failure NYHA (New York Heart Association) III or IV, clinically relevant myopathy,\n             history of myocardial infarction within the last 12 months, significant arrhythmias)\n\n          -  Concurrent severe uncontrolled medical illness (judged by the investigator) which\n             could impair the ability of the patient to participate in the trial (e.g.\n             uncontrolled infection, uncontrolled diabetes mellitus, active autoimmune disease)\n\n          -  Known dihydropyrimidine dehydrogenase (DPD) deficiency\n\n          -  Known hypersensitivity to trial drugs or hypersensitivity to any other component of\n             the trial drug\n\n          -  Definite contraindications for the use of corticosteroids or antihistamines as\n             premedication\n\n          -  Lack of physical integrity of the upper gastrointestinal tract or malabsorption\n             syndrome or history of inflammatory intestinal disease, or other disease which could\n             alter drug absorption\n\n          -  Psychiatric disorder precluding understanding of information on trial related topics,\n             giving informed consent, filling out QL forms, or interfering with compliance with\n             oral drug intake\n\n          -  Any concomitant drugs contraindicated for use with the trial drugs according to the\n             Swissmedic approved product information\n\n          -  Concurrent treatment with other experimental drugs or other anti-cancer therapy\n             and/or treatment in a clinical trial within 30 days prior to randomization"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "70 Years"
        }, 
        "enrollment": {
            "#text": "78", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01718808", 
            "org_study_id": "SAKK 41/10"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm A: Cetuximab", 
                    "Arm B: Cetuximab and Capecitabine"
                ], 
                "description": "Cetuximab 500 mg/m2 every second week (days 1, 15, 29, etc.) until progression or unacceptable toxicity", 
                "intervention_name": "Cetuximab", 
                "intervention_type": "Drug", 
                "other_name": "Erbitux"
            }, 
            {
                "arm_group_label": "Arm B: Cetuximab and Capecitabine", 
                "description": "Capecitabine 1000 mg/m2 bid p.o. (750 mg/m2 if creatinine clearance 30-50 ml/min according to Cockroft-Gault formula, on days 1-14 every 3 weeks, restart on day 22", 
                "intervention_name": "Capecitabine", 
                "intervention_type": "Drug", 
                "other_name": "Xeloda"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Capecitabine", 
                "Fluorouracil", 
                "Cetuximab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Metastatic Colorectal Cancer", 
            "KRAS", 
            "BRAF", 
            "Wild-type Metastatic", 
            "Cetuximab", 
            "Capecitabine", 
            "Phase II Trial", 
            "Elderly Patients"
        ], 
        "lastchanged_date": "February 7, 2014", 
        "location": [
            {
                "contact": {
                    "email": "vhess@uhbs.ch", 
                    "last_name": "Viviane Hess, MD", 
                    "phone": "41-61-265-5714"
                }, 
                "facility": {
                    "address": {
                        "city": "Basel", 
                        "country": "Switzerland", 
                        "zip": "CH-4031"
                    }, 
                    "name": "Universitaetsspital-Basel"
                }, 
                "investigator": {
                    "last_name": "Viviane Hess, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "attila.kollar@insel.ch", 
                    "last_name": "Attila Kollar, MD", 
                    "phone": "41-031-632-41-14"
                }, 
                "facility": {
                    "address": {
                        "city": "Bern", 
                        "country": "Switzerland", 
                        "zip": "CH-3010"
                    }, 
                    "name": "Inselspital, Bern"
                }, 
                "investigator": {
                    "last_name": "Attila Kollar, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "markus.borner@szb-chb.ch", 
                    "last_name": "Markus Borner, Prof.", 
                    "phone": "41-32-324-3714"
                }, 
                "facility": {
                    "address": {
                        "city": "Biel", 
                        "country": "Switzerland", 
                        "zip": "CH-2501"
                    }, 
                    "name": "Spitalzentrum Biel"
                }, 
                "investigator": {
                    "last_name": "Markus Borner, Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "betticherd@h-fr.ch", 
                    "last_name": "Daniel Betticher, MD", 
                    "phone": "41-26-426-7240"
                }, 
                "facility": {
                    "address": {
                        "city": "Fribourg", 
                        "country": "Switzerland", 
                        "zip": "1708"
                    }, 
                    "name": "Hopital Fribourgeois"
                }, 
                "investigator": {
                    "last_name": "Daniel Betticher, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "arnaud.roth@hcuge.ch", 
                    "last_name": "Arnaud Roth, MD", 
                    "phone": "41-22-372-7744"
                }, 
                "facility": {
                    "address": {
                        "city": "Geneva", 
                        "country": "Switzerland", 
                        "zip": "CH-1211"
                    }, 
                    "name": "Hopital Cantonal Universitaire de Geneve"
                }, 
                "investigator": {
                    "last_name": "Arnaud Roth, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Dorothea.Wagner@chuv.ch", 
                    "last_name": "Dorothea A. Wagner, MD", 
                    "phone": "41-21-314-4530"
                }, 
                "facility": {
                    "address": {
                        "city": "Lausanne", 
                        "country": "Switzerland", 
                        "zip": "CH-1011"
                    }, 
                    "name": "Centre Hospitalier Universitaire Vaudois"
                }, 
                "investigator": {
                    "last_name": "Dorothea A. Wagner, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ralph.winterhalder@ksl.ch", 
                    "last_name": "Ralph Winterhalder, MD", 
                    "phone": "+41 41 205 58 75"
                }, 
                "facility": {
                    "address": {
                        "city": "Luzern", 
                        "country": "Switzerland", 
                        "zip": "6000"
                    }, 
                    "name": "Kantonsspital Luzern"
                }, 
                "investigator": {
                    "last_name": "Ralph Winterhalder, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "roman.inauen@stgag.ch", 
                    "last_name": "Roman Inauen, MD", 
                    "phone": "+41 71 686 11 11"
                }, 
                "facility": {
                    "address": {
                        "city": "Muensterlingen", 
                        "country": "Switzerland", 
                        "zip": "8596"
                    }, 
                    "name": "Kantonsspital Muensterlingen"
                }, 
                "investigator": {
                    "last_name": "Roman Inauen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dieter.koeberle@kssg.ch", 
                    "last_name": "Dieter Koeberle, MD", 
                    "phone": "41-71-494-1111"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Gallen", 
                        "country": "Switzerland", 
                        "zip": "CH-9007"
                    }, 
                    "name": "Kantonsspital - St. Gallen"
                }, 
                "investigator": {
                    "last_name": "Dieter K\u00f6berle, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "daniel.rauch@spitalstsag.ch", 
                    "last_name": "Daniel Rauch", 
                    "phone": "+41 33 226 26 45"
                }, 
                "facility": {
                    "address": {
                        "city": "Thun", 
                        "country": "Switzerland", 
                        "zip": "3600"
                    }, 
                    "name": "SpitalSTS AG Simmental-Thun-Saanenland"
                }, 
                "investigator": {
                    "last_name": "Daniel Rauch, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sabina.schacher@ksw.ch", 
                    "last_name": "Sabina Schacher-Kaufmann, MD", 
                    "phone": "41-52-266-2552"
                }, 
                "facility": {
                    "address": {
                        "city": "Winterthur", 
                        "country": "Switzerland", 
                        "zip": "CH-8400"
                    }, 
                    "name": "Kantonsspital Winterthur"
                }, 
                "investigator": {
                    "last_name": "Sabina Schacher-Kaufmann, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lwidmer@onkozentrum.ch", 
                    "last_name": "Lucas Widmer, MD", 
                    "phone": "41-44-387-3780"
                }, 
                "facility": {
                    "address": {
                        "city": "Zurich", 
                        "country": "Switzerland", 
                        "zip": "CH-8032"
                    }, 
                    "name": "Klinik Hirslanden"
                }, 
                "investigator": {
                    "last_name": "Lucas Widmer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Bernhard Pestalozzi, MD", 
                    "phone": "41-44-255-2214"
                }, 
                "facility": {
                    "address": {
                        "city": "Zurich", 
                        "country": "Switzerland", 
                        "zip": "CH-8091"
                    }, 
                    "name": "UniversitaetsSpital Zuerich"
                }, 
                "investigator": {
                    "last_name": "Bernhard Pestalozzi, Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mathias.schmid@triemli.zuerich.ch", 
                    "last_name": "Mathias Schmid, Prof", 
                    "phone": "+41 44 466 11 11"
                }, 
                "facility": {
                    "address": {
                        "city": "Z\u00fcrich", 
                        "country": "Switzerland", 
                        "zip": "8063"
                    }, 
                    "name": "Stadtspital Triemli"
                }, 
                "investigator": {
                    "last_name": "Mathias Schmid, Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Cetuximab Monotherapy and Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With KRAS- and BRAF Wild-type Metastatic Colorectal Cancer. A Multicenter Phase II Trial", 
        "overall_contact": {
            "email": "scarlett.keunecke@sakk.ch", 
            "last_name": "Scarlett Keunecke", 
            "phone": "+41 31 389 94 64"
        }, 
        "overall_contact_backup": {
            "email": "Christiane.Pilop@sakk.ch", 
            "last_name": "Christiane Pilop, MD", 
            "phone": "+41 31 389 93 49"
        }, 
        "overall_official": [
            {
                "affiliation": "Kantonsspital Graub\u00fcnden", 
                "last_name": "Dirk Kienle, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Kantonsspital Graub\u00fcnden", 
                "last_name": "Roger von Moos, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Luzerner Kantonsspital", 
                "last_name": "Ralph Winterhalder, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Cantonal Hospital of St. Gallen", 
                "last_name": "Dieter K\u00f6berle, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "A progression event is defined as (whichever occurs first):\nProgressive disease (PD) assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\nDeath of any cause\nStarting of second line treatment\nNo tumor assessment 85 days (+/- 7 days) after registration which shows stabilisation or response Patients without tumor assessment at week 12 but with a later assessment showing absence of progression without subsequent treatment will be counted as a progression free at week 12", 
            "measure": "Progression free survival in week 12", 
            "safety_issue": "No", 
            "time_frame": "in week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01718808"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Quality of life  (QL)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, in week 7, 13 and 19"
            }, 
            {
                "measure": "Adverse events (CTCAE v 4.0)", 
                "safety_issue": "Yes", 
                "time_frame": "Adverse events are assessed by Common terminology criteria for adverse events (CTCAE) v4.0. From randomization until 30 days after end of treatment (estimated up to 2 years)."
            }, 
            {
                "measure": "Overall Response (OR)", 
                "safety_issue": "No", 
                "time_frame": "Before start of treatment. In week 13 and every 12 weeks up to 2 years."
            }, 
            {
                "measure": "Progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "PFS will be calculated sustained from randomization until documented PD or death, whichever occurs first (estimated up to 2 years)."
            }, 
            {
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Overall survival will be calculated from randomization until death (estimated up to 2 years)."
            }, 
            {
                "measure": "Overall treatment utility (OTU) (predefined composite endpoint including clinical benefit, tolerability and acceptability of the treatment)", 
                "safety_issue": "No", 
                "time_frame": "Until week 19."
            }
        ], 
        "source": "Swiss Group for Clinical Cancer Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Swiss Group for Clinical Cancer Research", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2014"
    }
}